๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 11 Shanghai 9 Nanjing 4 Changsha 4 Hangzhou 3
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing11 Shanghai9 Nanjing4 Changsha4 Hangzhou3
All 26 locations
Target enrolment
to

Trials with a site in Beijing

11 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer
NCT07790510Metastatic Colorectal Cancer (CRC)
Haisco Pharmaceutical Group Co., Ltd.
Phase 1/2
180
Beijing
2026-08-12
Not yet open
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD
NCT07658339COPD (Chronic Obstructive Pulmonary Disease)
Haisco Pharmaceutical Group Co., Ltd.
Phase 3
387
Beijing
2026-07-11
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD
NCT07583849COPD (Chronic Obstructive Pulmonary Disease)
Haisco Pharmaceutical Group Co., Ltd.
Phase 3
376
Beijing
2026-05-24
Recruiting
Phase โ…ข Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
NCT07390123IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.
Phase 3
370
Huangshan City, Wuhu, Beijing, Zhanjiang, Changsha, Changchun, Linyi, Shanghai
2026-04-07
Recruiting
Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation
NCT07561554Solid Tumors (Phase 1)
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
159
Beijing
2026-03-06
Recruiting
A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
NCT07616700IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
73
Beijing
2025-08-25
Recruiting
Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation
NCT07158710Malignant Brain Tumors
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
159
Beijing, Fuzhou, Guangzhou, Changchun, Shanghai
2025-08-15
Recruiting
Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment
NCT07152288Paroxysmal Nocturnal Hemoglobinuria (PNH)
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
24
Beijing
2025-05-29
By invitation
A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion
NCT06820749Asthma Bronchiale, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
309
Beijing
2024-12-10
Recruiting
Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation
NCT06536400Solid Tumors
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
316
Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Changsha, Nanjing, Shanghai
2024-06-25
Recruiting
Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation
NCT06050980NSCLC
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
220
Beijing, Chongqing, Fuzhou, Nanning, Harbin, Luoyang, Zhengzhou, Changsha
2023-03-27
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 11 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

9 of the 11 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 0 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 11 studies
PhaseStudiesRecruitingShare
Phase 15545.5%
Phase 33227.3%
Phase 22118.2%
Phase 1/2119.1%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Haisco Pharmaceutical Group Co., Ltd.119
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.